文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

索拉非尼联合经动脉化疗栓塞治疗伴有下腔静脉瘤栓的肝细胞癌患者的长期生存：2例报告及文献复习

Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.

作者信息

Gao Heng-Jun, Xu Li, Zhang Yao-Jun, Chen Min-Shan

机构信息

Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, P. R. China.

出版信息

Chin J Cancer. 2014 May;33(5):259-64. doi: 10.5732/cjc.013.10133. Epub 2013 Dec 11.

DOI:10.5732/cjc.013.10133
PMID:24325788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4026547/
Abstract

The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus formation in the main vasculature is extremely poor. Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC. In this study, we report two HCC patients with inferior vena cava tumor thrombus who underwent the combination treatment. The overall survival times for these two patients were 44 months and 35 months, respectively. Our report suggests that sorafenib combined with transarterial chemoembolization may be a viable choice for patients with advanced HCC even with inferior vena cava tumor thrombus. Further studies are required to verify the efficacy and safety of this combination therapy for patients with advanced HCC with inferior vena cava tumor thrombus.

摘要

在主要脉管系统中形成肿瘤血栓的肝细胞癌（HCC）预后极差。索拉非尼联合经动脉化疗栓塞术是一种针对晚期HCC的新型治疗方法。在本研究中，我们报告了两名接受联合治疗的伴有下腔静脉肿瘤血栓的HCC患者。这两名患者的总生存时间分别为44个月和35个月。我们的报告表明，索拉非尼联合经动脉化疗栓塞术对于即使伴有下腔静脉肿瘤血栓的晚期HCC患者可能是一种可行的选择。需要进一步研究来验证这种联合治疗对伴有下腔静脉肿瘤血栓的晚期HCC患者的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6433/4026547/7307e2af5c67/cjc-33-05-259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6433/4026547/29c20d9ac777/cjc-33-05-259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6433/4026547/7307e2af5c67/cjc-33-05-259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6433/4026547/29c20d9ac777/cjc-33-05-259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6433/4026547/7307e2af5c67/cjc-33-05-259-g002.jpg

相似文献

[1]
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.

Chin J Cancer. 2014-5

[2]
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.

Int Surg. 2015-5

[3]
Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.

Oncol Res Treat. 2024

[4]
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.

BMC Cancer. 2017-9-12

[5]
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.

Clin Mol Hepatol. 2016-3

[6]
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].

Gan To Kagaku Ryoho. 2015-11

[7]
Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.

Indian J Cancer. 2017

[8]
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.

Clin Radiol. 2014-12

[9]
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.

J Dig Dis. 2015-3

[10]
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Clin J Gastroenterol. 2015-10

引用本文的文献

[1]
Multi-algorithms analysis for pre-treatment prediction of response to transarterial chemoembolization in hepatocellular carcinoma on multiphase MRI.

Insights Imaging. 2023-2-28

[2]
Hepatocellular carcinoma with intra-atrial tumor extension identified on Tc-labeled macroaggregated albumin single photon emission computed tomography/computed tomography.

Indian J Nucl Med. 2016

[3]
Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.

Chin J Cancer. 2016-8-24

[4]
Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus.

Onco Targets Ther. 2016-7-12

本文引用的文献

[1]
Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: results of a retrospective cohort study.

Ann Surg Oncol. 2012-9-7

[2]
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Radiology. 2012-3-21

[3]
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

J Hepatol. 2012-4

[4]
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

J Hepatol. 2012-3-10

[5]
Hepatocellular carcinoma.

Lancet. 2012-2-20

[6]
Treatment outcomes of surgical resection for hepatocellular carcinoma with inferior vena cava invasion and/or thrombosis.

Hepatogastroenterology. 2011

[7]
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Cancer. 2011-6-28

[8]
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Int J Cancer. 2010-12-15

[9]
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

Leukemia. 2011-2-4

[10]
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

JAMA. 2010-11-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索